|
|
|
|
|
|
By Evan Shirley and Janel Firestein, Clarkston Consulting | Novo Holdings, the parent company to Novo Nordisk, announced a deal last week to acquire Catalent, the global CDMO, at a value of $16.5 billion. In the same breath, Novo Holdings announced they will sell three sites directly to Novo Nordisk, implying that the rest of the assets of the company will continue to operate as a stand-alone CDMO. This article unpacks the acquisition, discussing questions such as “what does it mean for customers?” and “does this deal reshape the CDMO market?” |
|
|
Vaccine Manufacture From The U.K. To Brazil And Saudi Arabia | By Louis Garguilo, chief editor, Outsourced Pharma | Why is Professor Thomas Rademacher’s U.K.-based vaccine-creating biotech so important that Saudi Arabia has based the establishment of the Kingdom’s first vaccine manufacturing facility on the company? The narrative starts in Brazil. |
|
|
Osmotic Controlled-Release Oral Drug Delivery: A Closer Look | By Rajendran (Raj) Arunagiri | Osmotic controlled-release drug delivery is not often spoken about, but it is a useful oral drug formulation technology. This article shares the mechanisms of the elements of oral dosage, including the semi-permeable membrane, pore-forming agents, and more, as well as advantages and applications of this type of drug delivery. |
|
|
|
|
Effects Of The Ongoing Pandemic On Bupivacaine HCI Supply | White Paper | By Hamid Parsa, Cambrex | Throughout the pandemic, painkiller and sedative demands spiked. Drug manufacturers and CDMOs have become critical in efforts to stabilize the supply of bupivacaine HCl and other essential drugs. |
|
|
|
|
|
|
Nasal Spray Development And Manufacturing Services | Catalent | A partner with experts who are adept at working with complex, sensitive, and potent APIs, screening for the optimal formulation, and scaling up efficiently is vital for successful trials and commercialization. |
|
|
Drug Product Contract Manufacturing Brochure | AbbVie | AbbVie Contract Manufacturing delivers advantages beyond a typical CMO to the drug product market. As a leading pharmaceutical developer and manufacturer, our large and diverse scientific team brings an extensive depth of knowledge and experience. |
|
|
OUTSOURCED PHARMA CAPACITY UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
